NCT00876460 - BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase I | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

September 30, 2012

Study Completion Date

July 31, 2015

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

BIBF 1120 M + docetaxel M

BIBF 1120 Medium dose bid + docetaxel 60 mg/m2

DRUG

BIBF 1120 M + docetaxel H

BIBF 1120 Medium dose bid + docetaxel 75mg/m2

DRUG

BIBF 1120 H + docetaxel H

BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2

DRUG

BIBF 1120 L + docetaxel M

BIBF 1120 Low dose bid + docetaxel 60 mg/m2

DRUG

BIBF 1120 H + docetaxel M

BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2

Trial Locations (2)

1199.29.002 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

1199.29.001 Boehringer Ingelheim Investigational Site, Osaka-Sayamashi, Osaka